Insilico Medicine Doses First Patient With AI-Designed Pan-TEAD Inhibitor

Insilico Medicine, a clinical-stage biotechnology company leveraging generative AI for drug discovery, has dosed the first patient in its global Phase I trial of ISM6331, a novel pan-TEAD inhibitor for the treatment of mesothelioma and other solid tumors. The trial, conducted in both China and the United States, aims to evaluate the safety, tolerability…